Dynavax Technolo Stock Price, News & Analysis

Deep Track Capital, owning 14.82% of Dynavax Technologies (DVAX), issued a letter to shareholders advocating for the election of four nominees to the Board at the June 11, 2025 Annual Meeting. The letter highlights Dynavax's underperformance, including missed 2024 targets for Heplisav (U.S. sales of $268M vs $275M target, market share of 44% vs 47% target). The company's stock has underperformed the Nasdaq Biotechnology Index, falling 17% over one year and 15% over three years. Deep Track argues that without new board perspectives, critical questions about strategic direction and capital allocation will remain unaddressed. The investment firm defends its nominees' qualifications and long-term commitment, emphasizing their potential to bring valuable experience and investor perspective to address the company's challenges.

Dynavax Technologies (DVAX) urges stockholders to vote FOR all four of its director nominees at the June 11, 2025 Annual Meeting, opposing Deep Track's competing nominees. The company emphasizes its successful strategic repositioning since 2019, delivering a 203% total stockholder return over five years, significantly outperforming vaccine peers (9%) and the S&P Biotechnology Index (-17%). The board nominees - Brent MacGregor, Scott Myers, Lauren Silvernail, and Elaine Sun - bring critical expertise in biotech and vaccines. Independent proxy firms ISS and Egan-Jones support Dynavax's nominees, with ISS criticizing Deep Track's misleading TSR analysis. The company highlights HEPLISAV-B's market leadership, strong financial results, and successful business development generating over $950M in revenue (2020-2022). Dynavax has completed 85% of its $200M share repurchase program authorized in November 2024.

Dynavax Technologies (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, announced its upcoming presentation at William Blair's 45th Annual Growth Stock Conference on June 3rd at 2:40 p.m. CT. The presentation will be accessible via webcast through the company's investor relations website.

Dynavax currently markets two commercial products: HEPLISAV-B® vaccine, approved in the U.S., EU, and UK for hepatitis B virus prevention in adults 18 and older, and CpG 1018® adjuvant, which is used in HEPLISAV-B and various COVID-19 vaccines.

Deep Track Capital, owning 14.82% of Dynavax Technologies (NASDAQ: DVAX), strongly disagrees with ISS's recommendation regarding board elections. Deep Track criticizes ISS for ignoring key issues including Heplisav's market share decline from 44% in 2024 to 43% in Q1 2025, missing the Board's 47% target. The company also failed to achieve its $275 million annual sales goal. Deep Track highlights concerns about corporate governance, including an imbalanced board structure, and criticizes recent director appointments lacking vaccine expertise. The stock has underperformed, dropping 23% year-to-date and showing a 43% decline between key events. Deep Track urges shareholders to vote FOR their four director nominees to improve board oversight and maximize value.

Deep Track Capital, holding a 14.82% stake in Dynavax Technologies (NASDAQ: DVAX), has issued a critical letter to shareholders ahead of the 2025 Annual Meeting. The letter highlights significant concerns about DVAX's performance, including a 26% year-to-date share price decline and an 11% drop following Q1 2025 earnings.

The investment firm criticizes Dynavax's management for being complacent about Heplisav's slowing market share growth, which reached only 43% in Q1 2025, falling short of management's 60% target by 2030. Deep Track is nominating four directors to the board, aiming to bring shareholder-aligned perspective, vaccine commercialization expertise, and capital allocation experience.

The letter emphasizes that Dynavax failed to meet its 2024 targets of 47% market share and $275 million in U.S. sales for Heplisav, while questioning recent strategic decisions, including the new pandemic flu vaccine program.

Dynavax Technologies (DVAX) has filed an investor presentation defending against Deep Track's proxy contest ahead of its 2025 Annual Meeting. The company highlights its 203% total stockholder return over five years, significantly outperforming vaccine peers (9%) and the S&P Biotechnology Index (-17%). HEPLISAV-B® achieved $268 million in net product revenue in 2024 with 44% U.S. market share. Q1 2025 showed strong growth with HEPLISAV-B® revenue up 36% YoY to $65 million. The company generated over $950 million in revenue during 2020-2022 through pandemic-related business development. Dynavax has completed 85% of its $200 million share repurchase program authorized in November 2024. The company opposes Deep Track's proposal to monetize HEPLISAV-B® and return all cash to shareholders, arguing it would jeopardize long-term growth opportunities.

Dynavax Technologies (DVAX) issued a response to Deep Track Capital's investor presentation and mailed a letter to stockholders ahead of its 2025 Annual Meeting. The company reported strong Q1 2025 results with total revenue of $68.2M (34% YoY growth) and HEPLISAV-B® revenue of $65M (36% YoY growth). HEPLISAV-B® achieved ~43% U.S. market share. The company has completed $172M of its $200M share repurchase program. Dynavax announced new pipeline programs including Pandemic Influenza (Phase 1/2 in Q2 2025) and Lyme Disease (clinical development in 2027). The company urges stockholders to vote "FOR" its four director nominees on the GOLD proxy card, opposing Deep Track's proposal which they argue would harm long-term value. Dynavax has delivered 203% returns over five years, outperforming vaccine peers (9%) and the S&P Biotech Index (-17%).

Dynavax Technologies (DVAX) issued a correction to its stockholder letter regarding value generation metrics, revising from "$1 billion and 104% return" to "over $900 million and 62% return" versus the S&P Biotechnology Index. The company is currently engaged in a proxy battle with Deep Track Capital, defending its strategic direction and urging shareholders to vote for its four director nominees at the June 11, 2025 Annual Meeting.

The company reported strong Q1 2025 results with total revenue of $68.2 million (34% YoY increase), including HEPLISAV-B® revenue of $65 million (36% YoY increase). HEPLISAV-B® achieved ~43% U.S. market share. Dynavax has completed 85% of its $200 million share repurchase program and announced new pipeline programs including Pandemic Influenza and Lyme Disease vaccines.

The company expects 2025 Adjusted EBITDA of at least $75 million and HEPLISAV-B® full-year revenue in the top half of $305-325 million guidance range.

Dynavax (DVAX) reported strong Q1 2025 financial results, with HEPLISAV-B achieving record Q1 net product revenue of $65 million, up 36% year-over-year. The company's U.S. market share increased to 43%. Total revenues reached $68.2 million, a 34% increase from Q1 2024. However, DVAX reported a GAAP net loss of $96.1 million, primarily due to debt refinancing. The company is advancing its pipeline with several programs: a shingles vaccine with Phase 1/2 results expected in Q3 2025, a plague vaccine program funded by the DoD, and new initiatives in pandemic influenza and Lyme disease vaccines. Dynavax maintains its 2025 guidance with HEPLISAV-B revenue expected between $305-325 million. The company has completed 85% of its $200 million share repurchase program and holds $661.3 million in cash and equivalents.